The Relative Strength (RS) Rating for Harmony Biosciences stock jumped into a new percentile Thursday, with an increase from 70 to 83.
This proprietary rating tracks market leadership by showing how a stock's price movement over the last 52 weeks compares to that of other stocks on the major indexes.
Over 100 years of market history shows that the best stocks typically have an RS Rating north of 80 as they begin their biggest climbs.
Looking For The Best Stocks To Buy And Watch? Start Here
Is Harmony Biosciences Stock A Buy?
Harmony Biosciences stock is working on a cup with handle with a 40.93 buy point. See if the stock can break out in heavy volume.
The rare and other neurological disease pharmaceutical company showed 6% EPS growth last quarter. Sales rose 16%. Keep an eye out for the company's next round of numbers on or around Feb. 19.
Harmony Biosciences stock holds the No. 4 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals is the No. 1-ranked stock within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
